Cataracts, dry eyes, glaucoma and other eye problems become more common with age. But these can be treated — and sometimes ...

Knowing the risk factors of age-related macular degeneration (AMD) and consulting an ophthalmologist or optometrist can help ...

The RetinalGeniX™ imaging system is designed to allow routine screenings to be conducted by general practitioners, optometric ...

Clearside Biomedical, Inc. (NASDAQ:CLSD), currently valued at $81.15 million, is a biotechnology company focused on developing innovative therapies for blinding eye diseases using its proprietary SCS ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Charles Smith, who has age-related macular degeneration, has taken part in a series of trials over a 15-year period ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

Age-related macular degeneration (AMD) is a progressive eye condition that primarily affects people over the age of 50. AMD is a leading cause of vision loss in people over 50.

RetinalGenix Technologies Inc OTCQB:RTGN ("RetinalGenix" or the "Company"), announced today that it has achieved an important milestone in developing ...

The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...

The three trials were all testing an experimental once-monthly dosing regimen for Beovu, which is already approved for wet AMD as an injection into the eye every two or three months. Beovu is a ...